Merck & Co., Inc. (MRK) Shares Sold by Schnieders Capital Management LLC

Schnieders Capital Management LLC cut its stake in Merck & Co., Inc. (NYSE:MRK) by 7.0% during the 2nd quarter, Holdings Channel reports. The fund owned 10,644 shares of the company’s stock after selling 802 shares during the period. Schnieders Capital Management LLC’s holdings in Merck & Co., Inc. were worth $646,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Motco boosted its holdings in Merck & Co., Inc. by 9.0% in the first quarter. Motco now owns 62,384 shares of the company’s stock worth $3,398,000 after acquiring an additional 5,126 shares in the last quarter. Buckley Wealth Management LLC boosted its holdings in Merck & Co., Inc. by 47.9% in the first quarter. Buckley Wealth Management LLC now owns 82,106 shares of the company’s stock worth $4,472,000 after acquiring an additional 26,597 shares in the last quarter. Tyers Asset Management LLC boosted its holdings in Merck & Co., Inc. by 9.2% in the first quarter. Tyers Asset Management LLC now owns 72,688 shares of the company’s stock worth $3,959,000 after acquiring an additional 6,132 shares in the last quarter. Willingdon Wealth Management boosted its holdings in Merck & Co., Inc. by 161.3% in the first quarter. Willingdon Wealth Management now owns 93,985 shares of the company’s stock worth $5,119,000 after acquiring an additional 58,012 shares in the last quarter. Finally, Douglass Winthrop Advisors LLC boosted its holdings in Merck & Co., Inc. by 0.5% in the first quarter. Douglass Winthrop Advisors LLC now owns 297,187 shares of the company’s stock worth $16,188,000 after acquiring an additional 1,335 shares in the last quarter. 72.18% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Merck & Co., Inc. stock opened at $69.81 on Friday. The company has a market capitalization of $191.27 billion, a PE ratio of 17.54, a P/E/G ratio of 2.22 and a beta of 0.81. Merck & Co., Inc. has a 52 week low of $52.83 and a 52 week high of $72.89. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.33 and a quick ratio of 1.04.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Friday, July 27th. The company reported $1.06 EPS for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.03. The company had revenue of $10.47 billion during the quarter, compared to the consensus estimate of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. Merck & Co., Inc.’s revenue was up 5.4% on a year-over-year basis. During the same period last year, the business posted $1.01 earnings per share. On average, equities research analysts predict that Merck & Co., Inc. will post 4.27 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, October 5th. Investors of record on Monday, September 17th were given a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date of this dividend was Friday, September 14th. Merck & Co., Inc.’s payout ratio is 48.24%.

Several brokerages have issued reports on MRK. Zacks Investment Research raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $79.00 price objective for the company in a research note on Wednesday, September 26th. Guggenheim began coverage on Merck & Co., Inc. in a research note on Monday, October 8th. They issued a “buy” rating for the company. Morgan Stanley set a $74.00 price objective on Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Thursday, August 23rd. SunTrust Banks reissued a “buy” rating and issued a $77.00 price objective on shares of Merck & Co., Inc. in a research note on Thursday, August 16th. Finally, Bank of America increased their price objective on Merck & Co., Inc. from $70.00 to $74.00 and gave the stock a “buy” rating in a research note on Monday, July 30th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Merck & Co., Inc. currently has a consensus rating of “Buy” and a consensus price target of $69.61.

In related news, Chairman Kenneth C. Frazier sold 279,850 shares of the stock in a transaction that occurred on Tuesday, October 2nd. The stock was sold at an average price of $72.07, for a total transaction of $20,168,789.50. Following the completion of the sale, the chairman now directly owns 971,800 shares of the company’s stock, valued at $70,037,626. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Adam H. Schechter sold 107,360 shares of the stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $70.18, for a total value of $7,534,524.80. Following the sale, the executive vice president now directly owns 100,000 shares of the company’s stock, valued at $7,018,000. The disclosure for this sale can be found here. Insiders have sold 929,360 shares of company stock valued at $64,370,599 over the last ninety days. 0.32% of the stock is currently owned by company insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Article: What is a Leveraged Buyout (LBO)?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply